Table 1.
Studies fulfilling all inclusion criteria
| First author [Ref.], year | Study type | Total patients | Average time from symptom onset to treatment, h | Agent | Timing of post IAT BCVA examination | Coexisting arterial occlusions |
|---|---|---|---|---|---|---|
| Mercier 10, 2014 | Retrospective case series | 14 | 8.0 [4.5–17.0] |
tPA Mean: 35 mg, SD 13 |
6–12 months | None specified |
|
| ||||||
| Pettersen 11, 2005 | Retrospective case series | 6 | 9.7 [6.0–18.0] |
tPA Range: 10–30 mg |
2 days to 2.5 years | None specified |
|
| ||||||
| Butz 12, 2003 | Retrospective case series | 22 | 7.6 [4.0–11.0] |
Urokinase Mean: 642,000,SD 300K OR tPA Mean: 27 mg, SD 8 |
Not specified | Severe ICA stenosis (1) ICA occlusion (1) |
|
| ||||||
| Richard 13, 1999 | Retrospective case series | 53 | 14.0 [3.0–50.0] |
tPA Maximum: 40 mg |
3 months | None specified |
|
| ||||||
| Schumacher 14, 1993 | Retrospective case series | 23 | 15.4 [3.833–60.0] |
Urokinase Maximum: 1.2 million units OR tPA Maximum: 70 mg |
Immediately to 6 months | ICA occlusion (4) ICA stenosis (4) MCA occlusion (1) |
BCVA = Best corrected visual acuity; tPA = tissue plasminogen activator; K = thousand; ICA = internal carotid artery.